Weighted Deduction for Clinical Research Expenditure Upheld Under Section 35(2AB), Recognizing External Study Necessity

The Tribunal addressed three key issues regarding weighted deduction under Section 35(2AB) of the Income Tax Act for clinical research expenditure. It ruled that expenditure on Bio Analytical and Bio Equivalence Studies conducted outside the in-house R&D facility is eligible for weighted deduction, even without Form 3CL certification. The Tribunal upheld the Gujarat HC's binding precedent and recognized that clinical trials necessarily require external facilities. Consequently, the Tribunal dismissed the Revenue's appeals and allowed the weighted deduction for the assessment years.

---

---

1. ISSUES PRESENTED and CONSIDERED

The core legal questions considered by the Tribunal in these appeals are:

(a) Whether weighted deduction under Section 35(2AB) of the Income Tax Act, 1961 is allowable in respect of expenditure incurred on Bio Analytical and Bio Equivalence Studies conducted outside the "in-house" R&D facility approved by the Department of Scientific and Industrial Research (DSIR), when such expenditure is not certified by the prescribed authority in Form 3CL.

(b) Whether the decision of the Gujarat High Court in the case of Cadila Healthcare Ltd., which allowed weighted deduction on such expenditure, remains binding and applicable, despite the Apex Court remitting related issues back to the Gujarat High Court for fresh adjudication.

(c) Whether the expenditure incurred on clinical trials, which necessarily involves external facilities such as hospitals and medical practitioners, can be treated as expenditure incurred on in-house scientific research for the purpose of weighted deduction under Section 35(2AB).

2. ISSUE-WISE DETAILED ANALYSIS

Issue (a): Allowability of weighted deduction on expenditure incurred outside approved in-house R&D facility without Form 3CL certification

Relevant legal framework and precedents: Section 35(2AB) of the Income Tax Act provides for weighted deduction on expenditure incurred on scientific research related to the business carried out by the assessee. The prescribed authority (DSIR) certifies the expenditure eligible for such weighted deduction through forms such as Form 3CM (for in-house R&D) and Form 3CL (for outsourced R&D). The Revenue's position was that only expenditure certified in Form 3CL for outsourced research is eligible for weighted deduction, and expenditure outside the in-house facility without such certification is not allowable.

Court's interpretation and reasoning: The Tribunal examined the nature of Bio Analytical and Bio Equivalence Studies, which form part of clinical drug trials essential for product approvals. These studies require hospital-type facilities and cooperation from medical professionals and volunteers, making it impractical to conduct them entirely within the in-house R&D facility. The Tribunal noted that the expenditure was wholly and exclusively incurred for scientific research and development and that the in-house R&D facility was duly approved by DSIR with Form 3CM submitted.

The Tribunal relied on the Explanation to clause (1) of Section 35(2AB), which expressly includes clinical drug trials as part of scientific research expenditure eligible for weighted deduction. It was held that mere absence of Form 3CL certification for expenditure incurred outside the in-house facility should not lead to disallowance if the expenditure is genuinely for scientific research.

Key evidence and findings: The assessee submitted Forms 3CM for the in-house facility and demonstrated that the expenditure on Bio Analytical and Bio Equivalence Studies was integral to clinical trials and product/process research. The Tribunal also noted that the prescribed authority's report (Form 3CL) is a report to the Director General (Income Tax Exemptions) and not a prerequisite for disallowance.

Application of law to facts: Applying the statutory provisions and Explanation, the Tribunal concluded that expenditure on clinical trials conducted outside the in-house R&D facility, but integral to the research process, qualifies for weighted deduction under Section 35(2AB).

Treatment of competing arguments: The Revenue argued that only expenditure certified in Form 3CL is eligible and relied on the absence of such certification for the disputed expenditure. The Tribunal rejected this narrow interpretation, emphasizing the substance over form and the practical realities of clinical trials.

Conclusions: The Tribunal upheld the CIT(A)'s allowance of weighted deduction on expenditure incurred outside the in-house R&D facility, holding that such expenditure is eligible under Section 35(2AB) despite the absence of Form 3CL certification.

Issue (b): Binding nature of Gujarat High Court decision and effect of Apex Court remand

Relevant legal framework and precedents: The Gujarat High Court in Cadila Healthcare Ltd. held that expenditure incurred on drug trials outside the approved in-house R&D facility is eligible for weighted deduction under Section 35(2AB). The Apex Court had remitted related issues back to the Gujarat High Court for fresh adjudication but had not set aside the Gujarat High Court's judgment.

Court's interpretation and reasoning: The Tribunal observed that the Gujarat High Court's decision remains binding and has not been overruled or set aside. The Apex Court's remand was procedural, and until the Gujarat High Court delivers a fresh judgment, the earlier decision holds the field. The Tribunal noted that no contrary High Court judgment was placed on record.

Key evidence and findings: The Tribunal relied on the coordinate bench's earlier decisions in the assessee's own case for AYs 2011-12 and 2012-13, which followed the Gujarat High Court's ruling and were not disturbed by the Apex Court.

Application of law to facts: Given the identical nature of the issue in the present appeals, the Tribunal applied the binding precedent of the Gujarat High Court and its own coordinate bench's decisions.

Treatment of competing arguments: The Revenue contended that the issue was not finally settled due to the Apex Court remand. The Tribunal rejected this argument, holding that the existing High Court decision remains authoritative until altered.

Conclusions: The Tribunal held that the Gujarat High Court decision is binding and supports the allowance of weighted deduction on expenditure incurred outside the in-house R&D facility.

Issue (c): Nature of clinical trials expenditure and its classification as in-house scientific research

Relevant legal framework and precedents: The Explanation to Section 35(2AB) includes clinical drug trials as scientific research eligible for weighted deduction. The practical nature of clinical trials necessitates external collaboration beyond the physical in-house R&D facility.

Court's interpretation and reasoning: The Tribunal recognized that clinical trials require hospital-type infrastructure and involvement of medical professionals, volunteers, and patients, which cannot be replicated within the in-house R&D unit. Therefore, expenditure incurred outside the in-house facility is necessarily part of the in-house research process.

Key evidence and findings: The Tribunal referred to the coordinate bench's earlier findings and the Gujarat High Court's approval of such interpretation, emphasizing the substance of research activities over the location of expenditure.

Application of law to facts: The Tribunal applied the Explanation to Section 35(2AB) and judicial precedents to hold that clinical trials expenditure outside the in-house R&D facility qualifies as in-house scientific research expenditure.

Treatment of competing arguments: The Revenue's narrow interpretation focusing on physical location and certification was rejected in favor of a purposive interpretation recognizing the practical realities of clinical research.

Conclusions: The Tribunal concluded that clinical trials expenditure, even when incurred outside the in-house R&D facility, is eligible for weighted deduction as part of in-house scientific research.

3. SIGNIFICANT HOLDINGS

The Tribunal preserved the following crucial legal reasoning verbatim from its coordinate bench decision:

"By very nature, the Clinical Trials cannot alone be done within research facility as they require cooperation from the Medical Doctors, Hospitals, Volunteers and patients, therefore such expenditure has to be necessarily spent outside the facility, but for the purpose of 'in-house' research."

"Merely because the prescribed authority segregated the expenditure in two parts, viz; those incurred within the in-house facility and those incurred outside by itself would not be sufficient to deny the benefit to the assessee under section 35(2AB) of the Act."

"As Ld. CIT(A) has followed the Coordinate Bench decision, which was approved by the Gujarat High Court and as no contrary High Court judgment has been placed on record, we approve the order of the CIT (A) and reject the Revenue contentions."

Core principles established include:

- The scope of scientific research expenditure under Section 35(2AB) includes clinical trials expenditure necessarily incurred outside the physical in-house R&D facility.

- Certification by the prescribed authority in Form 3CL, while relevant, is not an absolute prerequisite to deny weighted deduction if the expenditure is genuinely for in-house scientific research.

- Judicial precedents of the Gujarat High Court and coordinate benches of the Tribunal are binding and must be followed unless set aside by a higher authority.

Final determinations on each issue were as follows:

- Weighted deduction under Section 35(2AB) is allowable on expenditure incurred on Bio Analytical and Bio Equivalence Studies conducted outside the in-house R&D facility, provided such expenditure is integral to scientific research.

- The Gujarat High Court's decision in Cadila Healthcare Ltd. remains binding and supports the allowance of weighted deduction on such expenditure.

- Clinical trials expenditure, by its nature, involves external facilities and is part of in-house scientific research eligible for weighted deduction.

Accordingly, the Tribunal upheld the CIT(A)'s orders allowing the weighted deduction and dismissed the Revenue's appeals for both assessment years.

---